CSL511 Fibrinogen concentrate (human)

Phase 3Biologic

CSL511 Fibrinogen concentrate (human) is one of 5 biologic programs targeting Pseudomyxoma Peritonei. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pseudomyxoma PeritoneiRecruiting

Pseudomyxoma PeritoneiPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Pseudomyxoma Peritonei

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Mitosol

Beyfortus

1 4

CSL511 Fibrinogen concentrate (human)

CSL Behring

Phase 3

1 5

Molgramostim

SSavara Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Pseudomyxoma Peritonei

NCT06617897

Clinical

Trials by Indication[1]

Pseudomyxoma Peritonei1 trial

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Recruiting· CSL Behring logo

CSL Behring·Phase 3·NCT06617897·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CSL511 Fibrinogen concentrate (human). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CSL511 Fibrinogen concentrate (human) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CSL511 Fibrinogen concentrate (human). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CSL Behring

CSL511 Fibrinogen concentrate (human)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pseudomyxoma Peritonei1 trial

References

Drug Info

Quick Facts

Related News